| 产品描述: | STX-721 is an orally active, irreversible, covalent EGFR exon 20 insertion (ex20ins) inhibitor that selectively targets ex20ins-mutant dynamic protein states. STX-721 potently inhibits the kinase activity of EGFR ex20ins mutants (NPG, ASV, SVD). STX-721 inhibits phosphorylation of EGFR (pEGFR Y1068) and downstream ERK (pERK Thr202/Tyr204), and suppresses proliferation of ex20ins-mutant Ba/F3 cells and human NSCLC cell lines (NCI-H2073 ASV KI, CUTO-14 ASV). STX-721 induces tumor regression in EGFR ex20ins-mutant PDX/CDX models. STX-721 can be used for the study of non-small cell lung cancer (NSCLC) harboring EGFR or HER2 ex20ins mutations. |
| 体外研究: |
STX-721 (12.5-100 mg/kg, 口服,每日一次,20-42 天) 在 EGFR ex20ins 突变的 PDX/CDX 模型中表现出优异的抗肿瘤效果。 |
| 体内研究: |
STX-721 (10-1000 nM, 2 h) 抑制患者来源的 EGFR 外显子 20 插入突变细胞系 (MGH10080-1 SVD、MGH10022-1.19 GF) 中 EGFR (pEGFR Y1068) 和 ERK (pERK Thr202/Tyr204) 的磷酸化,其抑制活性高于在 EGFR WT NCI-H2073 细胞中的效果。 STX-721 (72 h) 在 CRISPR/Cas9 编辑的人源 NCI-H2073 癌细胞系中显示出抗增殖活性,对 NCI-H2073 EGFR V769_D770 insASV knock-in (KI) 细胞和 NCI-H2073 EGFR D770_N771 insSVD KI 细胞的 IC50 值分别为 10.1 nM 和 6.1 nM。 |
| 参考文献: |
1. Pagliarini RA, et al. STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. Clin Cancer Res. 2025 Jul 15;31(14):3002-3018. 2. Milgram BC, et al. Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer. J Med Chem. 2025 Feb 13;68(3):2403-2421. |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.703 ml |
8.516 ml |
17.033 ml |
| 5 mM |
0.341 ml |
1.703 ml |
3.407 ml |
| 10 mM |
0.17 ml |
0.852 ml |
1.703 ml |
| 50 mM |
0.034 ml |
0.17 ml |
0.341 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |